PT-141
June 20, 2023Promising
5/10
Purrptide digest
PT-141 (bremelanotide) is the cleaned-up, FDA-approved descendant of Melanotan II's accidental libido discovery — minus the tanning effect and minus the unapproved status. It's marketed as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, working through the central nervous system rather than blood flow like Viagra. Off-label use in men has grown steadily, since the mechanism — melanocortin receptor activation affecting libido centrally — isn't actually sex-specific.
What this means for you
🏃
If you care about weight/health
An FDA-approved option exists if libido is the specific issue, working through a completely different pathway than erectile-dysfunction drugs.
🩺
If you're a clinician
Approved for women, but the central melanocortin mechanism isn't sex-specific — off-label male use has real mechanistic grounding.
🔬
If you're a researcher
A central nervous system approach to sexual dysfunction, distinct from the vascular mechanism of PDE5 inhibitors like sildenafil.
💸
If you follow biotech
An approved drug with an expanding off-label use case is a clean, low-risk commercial story already in motion.
DI
Diamond et al.
AMAG Pharmaceuticals
For the nerds
Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder
Obstetrics & Gynecology · DOI: 10.1097/AOG.0000000000003500
Read full paper on PubMed →